GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » Valuation Rank

Solvonis Therapeutics (LSE:SVNS) Valuation Rank


View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Solvonis Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Solvonis Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » Valuation Rank
Comparable Companies
LSE:EQT LSE:SNT LSE:XSG XTER:SIE XPAR:SU ETN PH OSTO:ATCO A ITW EMR TSE:7011 XTER:ENR CMI OTIS AME XSWX:SCHN IR ROK OHEL:KNEBV XYL
Traded in Other Exchanges
J4I:Germany
Address
Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Website
https://www.solvonis.com
Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.